Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 2:21 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 2,406 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dysplasia Mild Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics of Avacopan (CCX168) in Participants With Mild or Moderate Hepatic Impairment

NCT06004934
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Avacopan
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Hialeah, Florida
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Nov 3, 2026, 2:21 AM EST
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Assessment of Penile Vibratory Stimulation Using the Viberect in Men With Mild-Moderate ED

NCT01715571
View directory record Official record
Conditions
Organic Erectile Dysfunction
Interventions
Viberect
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
30 Years to 70 Years · Male only
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2020
U.S. locations
2
States / cities
Baltimore, Maryland • Frederick, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Nov 3, 2026, 2:21 AM EST
Recruiting Not applicable Interventional

Feasibility, Usability, and Acceptability of Virtual Reality-Based Cognitive and Physical Rehabilitation in Individuals With Mild Cognitive Impairment

NCT07638748
View directory record Official record
Conditions
Mild Cognitive Impairment, Subjective Cognitive Decline (SCD)
Interventions
Virtual Reality (VR) sessions
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
55 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Nov 3, 2026, 2:21 AM EST
Completed Not applicable Interventional Results available

STIM+: PET Biomarker Education & Disclosure

NCT04818255
View directory record Official record
Conditions
Mild Cognitive Impairment, Dementia; Alzheimer's Type (Etiology)
Interventions
PET Biomarker Disclosure
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
55 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Nov 3, 2026, 2:21 AM EST
Completed Phase 2 Interventional

Safety and Efficacy Study of Q301 in Mild to Moderate Adolescents and Adults Atopic Dermatitis Patients

NCT03571620
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Q301 Cream, Vehicle
Drug
Lead sponsor
Qurient Co., Ltd.
Industry
Eligibility
12 Years to 70 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 24, 2020 · Synced Nov 3, 2026, 2:21 AM EST
Recruiting Phase 1 Interventional

A Study of CDX-622 in Participants With Mild to Moderate Asthma

NCT07330778
View directory record Official record
Conditions
Mild to Moderate Asthma
Interventions
CDX-622
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
San Francisco, California • Kansas City, Kansas • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Nov 3, 2026, 2:21 AM EST
Active, not recruiting No phase listed Observational

Poly-omic Predictors of Symptom Duration and Recovery for Adolescent Concussion

NCT04582682
View directory record Official record
Conditions
Concussion, Mild
Interventions
Not listed
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
5 Years to 24 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Syracuse, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Nov 3, 2026, 2:21 AM EST
Completed Not applicable Interventional Results available

Computer Training and Transcranial Direct Current Stimulation for Cognition in HIV

NCT03440840
View directory record Official record
Conditions
HIV-related Mild Neurocognitive Disorder
Interventions
Transcranial Direct Current Stimulation (tDCS), Computer-based Cognitive Training, Watching Educational Videos
Procedure · Behavioral
Lead sponsor
Nova Southeastern University
Other
Eligibility
50 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Nov 3, 2026, 2:21 AM EST
Completed Phase 1 Interventional

A Phase I Study in Asthma Patients Evaluating the Effect of Doses of FlutiForm™ on the Amount, if Any, of Cortisol Produced by the Adrenal Glands

NCT00657774
View directory record Official record
Conditions
Asthma
Interventions
FlutiForm 250/10 ug, FlutiForm 100/10 ug, Oral Prednisone 10mg, Placebo
Drug
Lead sponsor
SkyePharma AG
Industry
Eligibility
18 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
19
States / cities
Phoenix, Arizona • Anaheim, California • Long Beach, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2008 · Synced Nov 3, 2026, 2:21 AM EST
Completed Phase 1 Interventional

A Phase 1b Study to Assess the Safety and Anti-inflammatory Effects of Two Different Doses of SRT2104 in Patients With Ulcerative Colitis

NCT01453491
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
SRT2104
Drug
Lead sponsor
Sirtris, a GSK Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Anaheim, California • Bristol, Connecticut • Owensboro, Kentucky + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Nov 3, 2026, 2:21 AM EST
Completed Phase 2 Interventional

Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis

NCT04857112
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Low Dose MT-1303, High Dose MT-1303, Placebo, MT-1303
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
22
States / cities
Chandler, Arizona • Los Angeles, California • Rancho Cucamonga, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Nov 3, 2026, 2:21 AM EST
Completed Not applicable Interventional Results available

Cognitive Fitness for Depression in Older Adults

NCT04790630
View directory record Official record
Conditions
Depression Mild, Depressive Disorder, Major, Mild Cognitive Impairment
Interventions
Computerized Cognitive Remediation of Executive Functioning (CCR-EF), Active Control
Other
Lead sponsor
UConn Health
Other
Eligibility
60 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Nov 3, 2026, 2:21 AM EST
Completed Phase 1 Interventional

A Safety Study of TTP4000 in Subjects With Alzheimer's Disease

NCT01548430
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
TTP4000, Placebo
Drug
Lead sponsor
vTv Therapeutics
Industry
Eligibility
50 Years to 85 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Miami, Florida • Durham, North Carolina • High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 12, 2015 · Synced Nov 3, 2026, 2:21 AM EST
Terminated Phase 4 Interventional Results available

Prazosin and Cerebrospinal Fluid (CSF) Biomarkers in Mild Traumatic Brain Injury (mTBI)

NCT03221751
View directory record Official record
Conditions
Dementia
Interventions
prazosin hydrochloride, placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 26, 2024 · Synced Nov 3, 2026, 2:21 AM EST
Completed Phase 1 Interventional

Single Dose Escalation Study of PF-04360365 In Subjects With Mild To Moderate Alzheimer's Disease

NCT00733642
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
PF-04360365 1 mg/kg, PF-04360365 3 mg/kg, PF-04360365 5 mg/kg, PF-04360365 10 mg/kg
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Glendale, California • Eatontown, New Jersey • Oakhurst, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 28, 2009 · Synced Nov 3, 2026, 2:21 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

ALIGN: Aligning Medications With What Matters Most (Demonstration)

NCT06335953
View directory record Official record
Conditions
Polypharmacy, Alzheimer's Disease and Related Dementias, Mild Cognitive Impairment
Interventions
Pharmacist-led deprescribing intervention
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
65 Years and older
Enrollment
474 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Nov 3, 2026, 2:21 AM EST
Completed Not applicable Interventional

Combining a Caregiver Intervention With Aricept Treatment for Mild to Moderate Alzheimer's Disease

NCT00467766
View directory record Official record
Conditions
Alzheimer Disease, Caregivers
Interventions
Psychosocial information, counseling, and support, Donepezil (Aricept)
Behavioral · Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2007 · Synced Nov 3, 2026, 2:21 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Telehealth Advance Care Planning Intervention in Those With Mild Cognitive Impairment or Unrecognized Dementia

NCT04912245
View directory record Official record
Conditions
Advance Care Planning, Telemedicine, Mild Cognitive Impairment, Unrecognized Dementia, Dementia
Interventions
Telehealth visit
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
65 Years and older
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
7
States / cities
Bermuda Run, North Carolina • Conover, North Carolina • High Point, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Nov 3, 2026, 2:21 AM EST
Recruiting Phase 2 Interventional

Human Mesenchymal Stem Cells & Monoclonal Antibodies in the Treatment for Mild Cognitive Impairment or Early Alzheimer's Disease.

NCT07512362
View directory record Official record
Conditions
Mild Cognitive Impairment, Early Alzheimer's Disease, AD-MCI
Interventions
human Mesenchymal Stem Cells
Biological
Lead sponsor
Bernard (Barry) Baumel
Other
Eligibility
55 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Nov 3, 2026, 2:21 AM EST
Completed Phase 2 Interventional Results available

Candesartan's Effects on Alzheimer's Disease And Related Biomarkers

NCT02646982
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Placebo, Candesartan
Drug
Lead sponsor
Emory University
Other
Eligibility
50 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Nov 3, 2026, 2:21 AM EST
Not listed No phase listed Observational

Effect of LEQEMBI on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer's Disease

NCT06400368
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
Not listed
Lead sponsor
NeuroVision Imaging
Industry
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Nov 3, 2026, 2:21 AM EST
Completed Not applicable Interventional Results available

Serious Game-based Interventions in Patients With Mild Cognitive Impairment Outside the Clinic

NCT04920123
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Neuro-World
Device
Lead sponsor
University of Massachusetts, Amherst
Other
Eligibility
55 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Amherst, Massachusetts • Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Nov 3, 2026, 2:21 AM EST
Active, not recruiting Phase 2 Interventional

A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)

NCT06223360
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Low Dose Benfotiamine, High Dose Benfotiamine, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
50 Years to 89 Years
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
47
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Nov 3, 2026, 2:21 AM EST
Withdrawn Phase 2Phase 3 Interventional

AC-1204 Long-term Efficacy Response Trial (ALERT Protocol)

NCT01211782
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
caprylic triglyceride, long-chain triglyceride
Drug
Lead sponsor
Cerecin
Industry
Eligibility
55 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Dec 4, 2012 · Synced Nov 3, 2026, 2:21 AM EST